用醋酸格拉替雷（Copaxone）治疗的多发性硬化症患者外周血中CCL2（单核细胞趋化蛋白-1）和CCL5（调节激活正常T细胞表达和分泌因子）的水平。

CCL2 (MCP-1) and CCL5 (RANTES) levels in the peripheral blood of multiple sclerosis patients treated with Glatiramer Acetate (Copaxone).

作者信息

Losy Jacek, Michałowska-Wender Grazyna, Kurdyńska Aleksandra, Wender Mieczysław

机构信息

Neuroimmunological Unit, M. Mossakowski Medical Research Centre, Polish Academy of Sciences, Poznan, Poland.

出版信息

Folia Neuropathol. 2005;43(3):153-5.

PMID:16245210

Abstract

The MCP-1 and RANTES levels were measured in 20 multiple sclerosis patients before and after 1 year daily treatment with 20 mg of subcutaneously applied glatiramer acetate. The level of MCP-1 in serum from multiple sclerosis patients was lower than in control subjects. After one year of therapy with glatiramer acetate, the level of MCP-1 was almost identical with that at the starting point. The concentration of RANTES in MS, both before and after therapy, did not differ from the control subjects. The results emphasise the marked difference between the influence of glatiramer acetate and IFNbeta-1a on the expression of the studied cytokine. Glatiramer acetate therapy in multiple sclerosis is not so much an effective as a protective factor of antiinflammatory cytokines, it should be regarded as a down-regulator of proinflammatory agents.

摘要

对20例多发性硬化症患者在每天皮下注射20 mg醋酸格拉替雷治疗1年前后检测MCP-1和RANTES水平。多发性硬化症患者血清中的MCP-1水平低于对照组。醋酸格拉替雷治疗1年后，MCP-1水平与起始点几乎相同。治疗前后MS患者体内RANTES的浓度与对照组无差异。结果强调了醋酸格拉替雷和IFNβ-1a对所研究细胞因子表达影响的显著差异。醋酸格拉替雷治疗多发性硬化症与其说是一种有效的抗炎细胞因子保护因子，不如说是一种促炎因子的下调剂。